Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy

Table 5 Predictive factors for response and survival of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Ref.	Publishing year	Case number	Regimens	Poor predictive factors for response	Poor predictive factors for survival
Saeki et al[48]	2015	90	Low-dose FP with/without LV, IV, or IV plus IFN	DCP reduction or increase of < 20% from baseline to 2 wk after HAIC	Child-Pugh B, AFP reduction or increase of < 20% from baseline to 2 wk after HAIC, DCP reduction or increase < 20% from baseline to 2 wk after HAIC
Terashima et al[58]	2015	266	IFNα, 5-FU with/without CDDP	NLR ≥ 2.87 (cut-off, median value), presence of vascular invasion, presence of extrahepatic metastasis	NLR ≥ 2.87 (cut-off, median value), ECOG PS 1/2, Child-Pugh score 8-9, presence of extrahepatic metastasis, CRP ≥ 0.8 mg/dL, AFP ≥ 235.5 ng/mL
Zaitsu et al[59]	2014	44	Low-dose FP with/without IV, or IV plus IFN	ND	Child-Pugh B, serum transferrin < 190 mg/dL
Nouso et al[49]	2013	476	CDDP + 5-FU	ND	HBs antigen positive, Child-Pugh B, tumor number > 3, tumor size > 3 cm, presence of extrahepatic metastasis, Vp3/4, AFP > 400 ng/mL
Niizeki et al[60]	2012	71	Low-dose FP	VEGF ≥ 100 pg/mL	Child-Pugh B, VEGF ≥ 100 pg/mL, therapeutic effect SD + PD
Miyaki et al[61]	2012	249	Low-dose FP (106 patients); IFNα, 5-FU (143 patients)	HCV antibody negative, platelet count ≥ 15 × 104/μL	ECOG PS 1-2, Child-Pugh score 8-9, presence of extrahepatic metastasis, AFP ≥ 1000 ng/mL, abcence of additional therapy, theraputic effect SD + PD + DO
Obi et al[53]	2006	116	IFNα, 5-FU	Not detect	Vp4, Total bilirubin ≥ 1.0 mg/dL, theraputic effect PR + SD + PD

Low-dose FP: Low-dose 5-FU plus Cisplatin; LV: Leucovorin; IV: Isovorin; IFN: Interferon; CDDP: Cisplatin; DCP: Des-gamma-carboxy prothrombin; NLR: Neutrophil-to-lymphocyte ratio; ND: Not described; VEGF: Vascular endothelial growth factor; PS: Performance status; SD: Stable disease; PD: Progressive disease; DO: Drop-out; CR: Complete response.